Receptor-ligand Pair Typing and Prognostic Risk Model of Response or Resistance to Immune Checkpoint Inhibitors in Lung Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 May 8

PMID 37152010

Authors

Shengqiang Mao

Lingyan Zeng

Ying Yang

Zhiqiang Liu

Li Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, programmed cell death-1 (PD-1)-targeted treatment is ineffective for a sizable minority of patients, and drug resistance still cannot be overcome.

Methods: To explore the mechanisms of immunotherapy and identify new therapeutic opportunities in lung adenocarcinoma (LUAD), data from patients who did and did not respond to the anti-PD-1 treatment were evaluated using single-cell RNA sequencing, and bulk RNA sequencing were collected.

Results: We investigated the gene expression that respond or not respond to immunotherapy in diverse cell types and revealed transcriptional characteristics at the single-cell level. To ultimately explore the molecular response or resistance to anti-PD-1 therapy, cell-cell interactions were carried out to identify the different LRIs (ligand-receptor interactions) between untreated patients vs. no-responders, untreated patients vs. responders, and responders vs. non-responders. Next, two molecular subgroups were proposed based on 73 LRI genes, and subtype 1 had a poor survival status and was likely to be the immunosuppressive tumor subtype. Furthermore, based on the LASSO Cox regression analysis results, we found that , and can be distinct prognostic biomarkers, immune infiltration levels, and responses to immunotherapy in LUAD.

Discussion: Altogether, the effects of immunotherapy were connected to LRIs scores, indicating that potential medications targeting these LRIs could contribute to the clinical benefit of immunotherapy. Our integrative omics analysis revealed the mechanisms underlying the anti-PD-1 therapy response and offered abundant clues for potential strategies to improve precise diagnosis and immunotherapy.

References

Bonnardel J, TJonck W, Gaublomme D, Browaeys R, Scott C, Martens L . Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. Immunity. 2019; 51(4):638-654.e9. PMC: 6876284. DOI: 10.1016/j.immuni.2019.08.017. View

Le Tourneau C, Borcoman E, Kamal M . Molecular profiling in precision medicine oncology. Nat Med. 2019; 25(5):711-712. DOI: 10.1038/s41591-019-0442-2. View

Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S . Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022; 3(1):108-121. DOI: 10.1038/s43018-021-00292-8. View

Yuan M, Huang L, Chen J, Wu J, Xu Q . The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019; 4:61. PMC: 6914774. DOI: 10.1038/s41392-019-0099-9. View

Patil N, Nabet B, Muller S, Koeppen H, Zou W, Giltnane J . Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022; 40(3):289-300.e4. DOI: 10.1016/j.ccell.2022.02.002. View

Yu Y . Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Front Med. 2017; 12(2):229-235. DOI: 10.1007/s11684-017-0581-0. View

Wu S, Al-Eryani G, Roden D, Junankar S, Harvey K, Andersson A . A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021; 53(9):1334-1347. PMC: 9044823. DOI: 10.1038/s41588-021-00911-1. View

Cho J, Hong M, Ha S, Kim Y, Cho B, Lee I . Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Exp Mol Med. 2020; 52(9):1550-1563. PMC: 8080767. DOI: 10.1038/s12276-020-00493-8. View

Cao Q, Chen Y . Integrated Analyses of mA Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pan-Cancer. Int J Mol Sci. 2022; 23(19). PMC: 9570346. DOI: 10.3390/ijms231911182. View

10.

Wieder T, Eigentler T, Brenner E, Rocken M . Immune checkpoint blockade therapy. J Allergy Clin Immunol. 2018; 142(5):1403-1414. DOI: 10.1016/j.jaci.2018.02.042. View

11.

Kumar M, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond D . Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics. Cell Rep. 2018; 25(6):1458-1468.e4. PMC: 7009724. DOI: 10.1016/j.celrep.2018.10.047. View

12.

Longo S, Guo M, Ji A, Khavari P . Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat Rev Genet. 2021; 22(10):627-644. PMC: 9888017. DOI: 10.1038/s41576-021-00370-8. View

13.

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

14.

Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C . Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020; 73(5):1118-1130. DOI: 10.1016/j.jhep.2020.05.039. View

15.

Liu J, Qian C, Cao X . Post-Translational Modification Control of Innate Immunity. Immunity. 2016; 45(1):15-30. DOI: 10.1016/j.immuni.2016.06.020. View

16.

Browaeys R, Saelens W, Saeys Y . NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2019; 17(2):159-162. DOI: 10.1038/s41592-019-0667-5. View

17.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

18.

Inman B, Longo T, Ramalingam S, Harrison M . Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2016; 23(8):1886-1890. DOI: 10.1158/1078-0432.CCR-16-1417. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View